Plozalizumab (INN; hu1D9) is a humanized monoclonal antibody designed for the treatment of diabetic nephropathy and arteriovenous graft patency.Statement On A Nonproprietary Name Adopted By The USAN Council - Plozalizumab, American Medical Association.
This drug was developed by Takeda Pharmaceuticals International Co.
References